PR Newswire
NEW YORK, Oct. 10, 2023
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.
Company Webcast
Gerard Michel, CEO, will be participating in a fireside chat. The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://delcath.com/investors/ or https://wsw.com/webcast/lytham9/dcth/2022008. The webcast will also be archived and available for replay.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://lythampartners.com/fall2023invreg/.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by FDA, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-the-lytham-partners-fall-2023-investor-conference-301951598.html
SOURCE Delcath Systems, Inc.
